Moderate

Chemotherapy complications (chemotherapy-induced nausea & vomiting, oral mucositis, vesicant extravasation, anthracycline cardiotoxicity)

Oncology therapy complication · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Common non-neutropenic chemotherapy toxicities presenting to ED. Covers chemotherapy-induced nausea/vomiting (CINV), mucositis, vesicant extravasation (a time-critical injury), and anthracycline/HER2 cardiotoxicity. (Febrile neutropenia and tumour lysis have separate protocols.) Always confirm regimen, cycle day and last dose.

Red flags

  • Fever/neutropenia in any chemo patient (treat as sepsis)
  • Vesicant extravasation (anthracycline, vinca) - tissue-necrosing emergency
  • Intractable vomiting with dehydration/AKI/electrolyte derangement
  • New heart failure, arrhythmia or chest pain (cardiotoxicity/ACS)
  • Mucositis preventing oral intake (dehydration, infection portal)

Assessment

Differential diagnosis

  • Bowel obstruction / constipation / raised ICP (for vomiting)
  • Neutropenic sepsis (parallel consideration in any unwell chemo patient)
  • Infective mucositis (candida, HSV)
  • Cellulitis/abscess vs extravasation at cannula site
  • Cardiac: ACS, PE, fluid overload (for cardiotoxicity)

Investigations

  • FBC (always exclude neutropenia), U&E (dehydration/AKI from vomiting), glucose, calcium
  • Document chemotherapy agent(s), emetogenic risk, cycle day
  • For extravasation: identify the drug (vesicant vs irritant), examine site, mark area, photograph
  • For cardiotoxicity: ECG, troponin, BNP, echocardiogram (LVEF) - compare with baseline
  • Mucositis: assess severity (WHO grade), swabs if infection suspected, hydration/nutrition status

Management

  • ALWAYS check for neutropenia/sepsis in any unwell chemotherapy patient first
  • CINV: rehydrate, give antiemetics by emetogenic risk (5-HT3 antagonist + dexamethasone +/- NK1 antagonist for highly emetogenic; add metoclopramide/olanzapine for breakthrough)
  • EXTRAVASATION (vesicant e.g. anthracyclines, vinca alkaloids): STOP infusion immediately, do NOT flush, aspirate residual drug via cannula, remove cannula, elevate limb
  • Extravasation antidote/thermal measures by drug: anthracycline - cold compress + dexrazoxane; vinca alkaloids - WARM compress + hyaluronidase; urgent oncology/plastics referral
  • Mucositis: analgesia (topical + systemic/opioid), oral hygiene/saline rinses, antifungal/antiviral if infected, maintain hydration/nutrition, admit if unable to swallow/dehydrated
  • Cardiotoxicity: manage heart failure per standard pathway, hold cardiotoxic agent, urgent cardio-oncology/echo
  • Liaise with the patient's oncology team for all significant toxicity and dose modification

Drugs & doses

Ondansetron 8 mg IV/PO twice daily (CINV; caution QT) [verify local dose]
Dexamethasone 8-12 mg IV/PO once daily (antiemetic adjunct) [verify local dose]
Aprepitant 125 mg PO day 1 then 80 mg daily (NK1 antagonist, highly emetogenic regimens) [verify local dose]
Metoclopramide 10 mg IV/PO three times daily or olanzapine 5-10 mg PO once daily for breakthrough nausea [verify local dose]
Dexrazoxane IV within 6 h for anthracycline extravasation (specialist) [verify local dose]
Hyaluronidase SC around site for vinca alkaloid extravasation [verify local dose]
Topical analgesia (e.g. benzydamine/lidocaine mouthwash) + systemic opioids for mucositis [verify local dose]
Standard heart-failure therapy (ACE-i/beta-blocker/diuretic) for anthracycline cardiomyopathy [verify local dose]

Disposition

Extravasation/cardiotoxicity/severe mucositis/intractable CINV -> admit or urgent oncology review. Mild controlled symptoms -> discharge with antiemetics, oral care and oncology follow-up. Any neutropenic sepsis -> admit per that protocol.

Complications & pitfalls

  • Dehydration, AKI, electrolyte disturbance from CINV
  • Tissue necrosis / ulceration requiring debridement from extravasation
  • Secondary infection / sepsis via mucosal breakdown
  • Irreversible cardiomyopathy (anthracyclines, trastuzumab)
  • Malnutrition and treatment delay

Exam pearls

  • The first question for any sick chemo patient is: are they neutropenic/septic? Treat that in parallel
  • Extravasation of a vesicant is time-critical: STOP, aspirate (do not flush), then drug-specific measure - COLD + dexrazoxane for anthracyclines, WARM + hyaluronidase for vinca alkaloids
  • Match antiemetics to the regimen's emetogenic risk; olanzapine is excellent for refractory CINV
  • Anthracycline cardiotoxicity can be delayed by years - take a chemo history in any new cardiomyopathy
  • Always involve the patient's oncology team - toxicities drive dose adjustments

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.